Concurrent paclitaxel and radiation therapy for solid tumors

H. Choy, W. Akerley, M. Glantz, H. Safran, S. Graziano, C. Chung

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Combination radiation and chemotherapy has an intuitive appeal for improving cancer treatment. Experimental results suggest that paclitaxel plus radiation might produce additive or synergistic effects. Methods: A series of phase I and II trials to test tolerance and begin to evaluate effectiveness were performed on patients with non-small cell lung cancer, high-grade astrocytic brain tumors, and pancreatic and gastric cancers. Results: Tolerance of the combined drug and radiation programs was generally good. Esophagitis was dose-limiting for the intrathoracic tumors. Hematologic toxicity was mild, but peripheral neuritis and cutaneous reactions were common. Conclusions: These trials show that paclitaxel plus concurrent radiation is feasible at the dose levels and schedules tested. Antitumor responses have been observed.

Original languageEnglish (US)
Pages (from-to)310-318
Number of pages9
JournalCancer Control
Volume3
Issue number4
StatePublished - 1996

Fingerprint

Paclitaxel
Radiotherapy
Radiation
Drug Tolerance
Background Radiation
Neuritis
Esophagitis
Radiation Tolerance
Combination Drug Therapy
Pancreatic Neoplasms
Non-Small Cell Lung Carcinoma
Brain Neoplasms
Stomach Neoplasms
Neoplasms
Appointments and Schedules
Skin
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Choy, H., Akerley, W., Glantz, M., Safran, H., Graziano, S., & Chung, C. (1996). Concurrent paclitaxel and radiation therapy for solid tumors. Cancer Control, 3(4), 310-318.

Concurrent paclitaxel and radiation therapy for solid tumors. / Choy, H.; Akerley, W.; Glantz, M.; Safran, H.; Graziano, S.; Chung, C.

In: Cancer Control, Vol. 3, No. 4, 1996, p. 310-318.

Research output: Contribution to journalArticle

Choy, H, Akerley, W, Glantz, M, Safran, H, Graziano, S & Chung, C 1996, 'Concurrent paclitaxel and radiation therapy for solid tumors', Cancer Control, vol. 3, no. 4, pp. 310-318.
Choy H, Akerley W, Glantz M, Safran H, Graziano S, Chung C. Concurrent paclitaxel and radiation therapy for solid tumors. Cancer Control. 1996;3(4):310-318.
Choy, H. ; Akerley, W. ; Glantz, M. ; Safran, H. ; Graziano, S. ; Chung, C. / Concurrent paclitaxel and radiation therapy for solid tumors. In: Cancer Control. 1996 ; Vol. 3, No. 4. pp. 310-318.
@article{f4943249a45844c7ae9e9140cba3699f,
title = "Concurrent paclitaxel and radiation therapy for solid tumors",
abstract = "Background: Combination radiation and chemotherapy has an intuitive appeal for improving cancer treatment. Experimental results suggest that paclitaxel plus radiation might produce additive or synergistic effects. Methods: A series of phase I and II trials to test tolerance and begin to evaluate effectiveness were performed on patients with non-small cell lung cancer, high-grade astrocytic brain tumors, and pancreatic and gastric cancers. Results: Tolerance of the combined drug and radiation programs was generally good. Esophagitis was dose-limiting for the intrathoracic tumors. Hematologic toxicity was mild, but peripheral neuritis and cutaneous reactions were common. Conclusions: These trials show that paclitaxel plus concurrent radiation is feasible at the dose levels and schedules tested. Antitumor responses have been observed.",
author = "H. Choy and W. Akerley and M. Glantz and H. Safran and S. Graziano and C. Chung",
year = "1996",
language = "English (US)",
volume = "3",
pages = "310--318",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "4",

}

TY - JOUR

T1 - Concurrent paclitaxel and radiation therapy for solid tumors

AU - Choy, H.

AU - Akerley, W.

AU - Glantz, M.

AU - Safran, H.

AU - Graziano, S.

AU - Chung, C.

PY - 1996

Y1 - 1996

N2 - Background: Combination radiation and chemotherapy has an intuitive appeal for improving cancer treatment. Experimental results suggest that paclitaxel plus radiation might produce additive or synergistic effects. Methods: A series of phase I and II trials to test tolerance and begin to evaluate effectiveness were performed on patients with non-small cell lung cancer, high-grade astrocytic brain tumors, and pancreatic and gastric cancers. Results: Tolerance of the combined drug and radiation programs was generally good. Esophagitis was dose-limiting for the intrathoracic tumors. Hematologic toxicity was mild, but peripheral neuritis and cutaneous reactions were common. Conclusions: These trials show that paclitaxel plus concurrent radiation is feasible at the dose levels and schedules tested. Antitumor responses have been observed.

AB - Background: Combination radiation and chemotherapy has an intuitive appeal for improving cancer treatment. Experimental results suggest that paclitaxel plus radiation might produce additive or synergistic effects. Methods: A series of phase I and II trials to test tolerance and begin to evaluate effectiveness were performed on patients with non-small cell lung cancer, high-grade astrocytic brain tumors, and pancreatic and gastric cancers. Results: Tolerance of the combined drug and radiation programs was generally good. Esophagitis was dose-limiting for the intrathoracic tumors. Hematologic toxicity was mild, but peripheral neuritis and cutaneous reactions were common. Conclusions: These trials show that paclitaxel plus concurrent radiation is feasible at the dose levels and schedules tested. Antitumor responses have been observed.

UR - http://www.scopus.com/inward/record.url?scp=0029742594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029742594&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029742594

VL - 3

SP - 310

EP - 318

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 4

ER -